Who Paid My Doc
Shelly Reardon
Neurology with Special Qualifications in Child Neurology Austin, TX Medical Doctor
NPI 1053363366 CMS profile 47817
5301 Davis Ln Bldg A200, Austin, TX 78749
General payments
$17,112
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Shelly Reardon of Austin, TX is reported in the CMS Open Payments database as having received $17,112 across 523 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 87th percentile of Neurology with Special Qualifications in Child Neurology profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
7 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $2,148 | 95 | |
| 2024 | General | $2,106 | 95 | |
| 2023 | General | $4,601 | 105 | |
| 2022 | General | $1,390 | 65 | |
| 2021 | General | $847 | 58 | |
| 2020 | General | $410 | 20 | |
| 2019 | General | $5,611 | 85 |
Beside peers
- Shelly Reardon
- Neurology with Special Qualifications in Child Neurology median
- Middle half of Neurology with Special Qualifications in Child Neurology
- National median
In program year 2025, general payments to Shelly Reardon were reported at $2,148. Among 1,228 Neurology with Special Qualifications in Child Neurology profiles paid that year, the median was $276 and the middle half received between $87 and $1,522.
Show as a table
| Year | Shelly Reardon | Neurology with Special Qualifications in Child Neurology median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $5,611 | $262 | $68–$1,313 | $163 |
| 2020 | $410 | $188 | $46–$1,222 | $114 |
| 2021 | $847 | $183 | $45–$1,356 | $132 |
| 2022 | $1,390 | $229 | $72–$1,177 | $149 |
| 2023 | $4,601 | $269 | $93–$1,195 | $160 |
| 2024 | $2,106 | $300 | $98–$1,428 | $164 |
| 2025 | $2,148 | $276 | $87–$1,522 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Records
523 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Neurology with Special Qualifications in Child Neurology in Texas
Roy Elterman
Neurology with Special Qualifications in Child Neurology · Dallas, TX
Huda Zoghbi
Neurology with Special Qualifications in Child Neurology · Houston, TX
Diana Castro
Neurology with Special Qualifications in Child Neurology · Denton, TX
Shade Moody
Neurology with Special Qualifications in Child Neurology · Houston, TX
Mary Kay Koenig
Neurology with Special Qualifications in Child Neurology · Houston, TX
Michael Perry
Neurology with Special Qualifications in Child Neurology · Fort Worth, TX
Related records
Neurology with Special Qualifications in Child Neurology in Texas
Practitioners in the same specialty and state, ranked by reported value.
All Neurology with Special Qualifications in Child Neurology
Everyone recorded under this specialty, nationwide.
Doctors in Texas
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.